XENE - Company ID 0001582313
The table below shows Xenon Pharmaceuticals Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $7.50M | $0.00 | $0.00 | $9.43M | $18.44M | $32.17M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $300.94M | $210.39M | $167.51M | $105.77M | $75.46M | $50.52M |
| SG&A |
Xenon Pharmaceuticals Inc. reported annual revenue of $7.50M for fiscal year 2025. Over the 10 fiscal years shown, annual revenue declined from $15.58M (FY 2015) to $7.50M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $79.63M |
| $68.90M |
| $46.54M |
| $32.81M |
| $21.97M |
| $12.94M |
| Operating income | -$373.07M | -$279.30M | -$214.05M | -$129.14M | -$78.99M | -$31.30M |
| Income tax | $1.02M | -$4.09M | -$292.00K | $118.00K | -$6.00K | -$257.00K |
| Net income | -$345.91M | -$234.33M | -$182.39M | -$125.37M | -$78.88M | -$28.84M |
| EPS (diluted) | -$4.36 | -$3.01 | -$2.73 | -$2.06 | -$1.77 | -$0.81 |